Ua hōʻike ʻia ka lāʻau lapaʻau ʻo Race Oncology ʻo Zantrene e pale aku i nā ʻiʻo ʻiʻo puʻuwai kanaka mai ka make chemotherapy i hoʻokomo ʻia e anthracycline. ʻO ka Anthracycline nā lāʻau anti-cancer maikaʻi loa, akā hiki iā lākou ke hōʻeha nui i ka naʻau.
Ua hōʻike pū ʻia ka noiʻi preclinical i ka hiki iā Zantrene ke synergize me nā anthracyclines i kēia manawa e pepehi maikaʻi aku i nā maʻi maʻi maʻi umauma.
Ma muli o ke koʻikoʻi o ka loaʻa ʻana, e hele wikiwiki ʻo Zantrene i ke keʻena me kahi hoʻokolokolo Phase 2b i hoʻolālā ʻia no 2022 i nā maʻi maʻi maʻi umauma i ka nui o ka pōʻino o ka puʻuwai anthracycline.
Hāʻawi i ka hiki o ka hoʻihoʻi ʻana mai o nā lāʻau lapaʻau a me nā mea kūʻai mai nā hana hou a me nā hui pū ʻana o Zantrene/anthracycline.

ʻO kēia ka manawa mua i hōʻike ai ka lāʻau lapaʻau i ka hiki ke hoʻopaʻa i ka maʻi kanesa a pale i ka puʻuwai mai ka pōʻino anthracycline. Hāʻawi kēia ʻike i ka manaʻolana hou i ka miliona o nā maʻi maʻi maʻi maʻi ma ka honua holoʻokoʻa e hana ana i ka chemotherapy me nā anthracyclines a ke pilikia nei i ka pōʻino koʻikoʻi a mau loa i ko lākou naʻau.

Ua ʻike nui ʻia nā Anthracyclines ʻo ia ka lāʻau lapaʻau anticancer maikaʻi loa i kūkulu ʻia a hoʻohana ʻia i nā ʻano maʻi maʻi ʻē aʻe ma mua o nā ʻano lāʻau anti-cancer ʻē aʻe.^[1], me ka leukemias, lymphomas, neuroblastoma, kidney, ate, opu, uterine, thyroid, ovarian, sarcomas, bladder, akemāmā a me ka umauma maʻi 'aʻai. Eia nō naʻe, ʻo ka makaʻu i ka hopena ʻino o nā anthracyclines ma ka puʻuwai ua alakaʻi i ka nui oncologists e kaupalena i kā lākou hoʻohana ʻana i kēia mau lāʻau lapaʻau maikaʻi loa. Loaʻa i ka loaʻa ʻana o ka lāhui ke hoʻololi i ka hoʻohana ʻana i nā anthracyclines ma ka ʻae ʻana i nā oncologists e hoʻohana i kēia mau lāʻau ikaika i ko lākou hiki piha anti-cancer me ka makaʻu ʻole i ka pōʻino mau i ka puʻuwai.

ʻO ka Zantrene^® Ke alakaʻi ʻia nei ka papahana noiʻi palekana naʻau e nā mea noiʻi cardiotoxicity koʻikoʻi, ʻo Associate Professors Aaron Sverdlov a me Doan Ngo, i ka hui pū ʻana me ka ʻepekema ʻepekema Associate Professor Nikki Verrills, ma The University of Newcastle.

Ua ʻōlelo ʻo Associate Professor Aaron Sverdlov: "I kēia lā, ʻaʻole i loiloi ʻia ka manaʻo o ka maʻi maʻi maʻi ʻaʻole wale no ka cardiotoxic akā, ʻoiaʻiʻo, ʻaʻole i loiloi ʻia ka cardio-protection, ʻo ka hapa nui ma muli o ka 'maʻi-specific hoʻokokoke i ke olakino. Hōʻike kā mākou mau hopena e hiki iā Zantrene, kahi lāʻau anti-cancer maikaʻi, hiki ke hāʻawi i ka pale i nā hopena ʻona ma ka puʻuwai mai kekahi o nā mea lapaʻau maʻamau i hoʻohana ʻia, doxorubicin. ʻO kēia ka hōʻike mua o kona ʻano e hōʻike ana aia kahi lāʻau lapaʻau e hoʻopaʻa ʻia i ka maʻi kanesa a pale i ka puʻuwai! Hiki i kēia ke hoʻomaikaʻi i nā hopena olakino no nā mea maʻi maʻi maʻi a me nā mea ola ma o ka hoʻomaikaʻi ʻana i kā lākou mālama maʻi maʻi ʻoiai ke pale ʻana i ka ulu ʻana o ka maʻi cardiovascular.

ʻOiai he mea hoihoi hou kēia, ʻo Zantrene^® (bisantrene dihydrochloride) he moʻolelo lapaʻau lōʻihi, ua hoʻomohala ʻia i ka makahiki 1970 ma ke ʻano he puʻuwai palekana palekana i ka anthracyclines [2] ma mua o ka ʻae ʻia ma Farani i nā 1990s. ʻOiai ua hōʻoia ʻia ka palekana o ka puʻuwai o Zantrene ma mua o 50 mau hoʻokolohua lapaʻau^[3], ʻAʻole i pane ʻia ka nīnau inā hiki iā Zantrene ke pale i ka pōʻino o ka naʻau i hana ʻia e ka anthracyclines.

Ma ka ʻōlelo ʻana e pili ana i nā hopena noiʻi hou, ua ʻōlelo ʻo Race's Chief Scientific Officer, ʻo Dr Daniel Tillett: "No ka ʻike ʻana hiki iā Zantrene ke pale i ka puʻuwai mai ka chemotherapy aʻo ka pepehi ʻana i nā maʻi maʻi ʻoi aku ka maikaʻi o ka hopena 'maikaʻi loa o nā honua ʻelua. Hoʻohana ʻia nā anthracyclines i nā miliona o nā mea maʻi maʻi maʻi i kēlā me kēia makahiki, he paʻakikī ke hoʻonui i ka hiki ke hoʻomaʻamaʻa a me ke kālepa o kēia holomua!

hopena a

Ma kēia kŘkohu preclinical, pale ʻo Zantrene i nā puʻuwai puʻuwai mai ka pōʻino e doxorubicin aʻo ka hui pū ʻana me nā anthracyclines e pepehi maikaʻi i nā maʻi maʻi maʻi umauma.
Ua hoʻouna ʻo Race i kahi palapala patent e kamaʻilio ana i ka hui pū ʻana o Zantrene me kahi anthracycline no ka pale ʻana i ka puʻuwai o nā maʻi. ʻO kēia patent (inā hāʻawi ʻia) e hāʻawi i ka pale o ka hui ʻana o ka lāʻau a me kona hoʻohana lāʻau lapaʻau a hiki i 2041.
E holo wikiwiki ana kēia ʻike pale puʻuwai hou i ke keʻena kino. ʻO ka mōʻaukala lapaʻau nui o Zantrene e ʻae i kēia hui ʻana e holomua wikiwiki i ka clinically.
Ke hoʻomaka nei nā kūkākūkā holomua me nā kauka ma Australia e holo i kahi hoʻokolohua lapaʻau Phase 2b i nā poʻe maʻi maʻi maʻi maʻi maʻi i ka pōʻino o ka puʻuwai anthracycline.
Ke wehe nei kēia ʻike i nā manawa mākeke hou no Zantrene o nā ʻano like ʻole a me nā ʻoihana kūʻai like me ka ʻike mua ʻana ʻo Zantrene kahi mea hoʻopale FTO ikaika.

Nā Pākuʻi

Hana ʻia nā haʻawina holoholona ma Q4 CY2021/ Q1CY2022.
ʻO nā haʻawina preclinical hou e noiʻi inā hiki iā Zantrene ke pale i ka puʻuwai mai ka pōʻino e nā lāʻau chemotherapeutic ʻē aʻe i ʻike ʻia e hoʻopilikia i ka cardio-damage.
ʻO nā haʻawina hou e hoʻoholo ai i ka hana molekala o ka hana cardio-protection a Zantrene. Hiki i kēia ke ʻae i ka ʻike ʻana i nā hana pale hou o Zantrene.
Ka hoʻomohala ʻana i nā mea hoʻohui lāʻau hou a maikaʻi hoʻi me ka hoʻomaikaʻi ʻana i ka waiwai lapaʻau a me ka waiwai kālepa.
Ka hoʻomaka ʻana o kahi hoʻokolohua lapaʻau maʻi maʻi umauma Phase 2b ma 2022.

He aha e lawe ʻia mai kēia ʻatikala:

While this is an exciting new discovery, Zantrene® (bisantrene dihydrochloride) has a long clinical history, having been developed in the 1970s as a heart safer alternative to the anthracyclines[2] before approval in France in the 1990s.
Race’s discovery has the potential to revolutionize the use of anthracyclines by allowing oncologists to use these powerful drugs to their full anti-cancer potential without fear of permanent damage to the heart.
Ma muli o ke koʻikoʻi o ka loaʻa ʻana, e hele wikiwiki ʻo Zantrene i ke keʻena me kahi hoʻokolokolo Phase 2b i hoʻolālā ʻia no 2022 i nā maʻi maʻi maʻi umauma i ka nui o ka pōʻino o ka puʻuwai anthracycline.